Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9706—Algae
  • A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/02—Algae
  • A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/06—Preparations for care of the skin for countering cellulitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D11/00—Solvent extraction
  • B01D11/02—Solvent extraction of solids
  • B01D11/0288—Applications, solvents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/10—Preparation or pretreatment of starting material
  • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/10—Preparation or pretreatment of starting material
  • A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/30—Extraction of the material
  • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
  • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/50—Methods involving additional extraction steps
  • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/74—Biological properties of particular ingredients
  • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
  • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
  • A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95

Definitions

• the ratio of the Mastocarpus stellatus to the acid may also be adjusted depending on the desired degree of hydrolysis.
• a suitable ratio is, for example, about 3-6% of sulfuric acid, preferably about 4.5% of sulfuric acid.
• the present invention provides a cosmetic composition comprising the Mastocarpus stellatus extract of the present invention and a cosmetically acceptable excipient.
• the cosmetic composition of the present invention is intended for topical application.
• excipients commonly used in the preparation of cosmetic preparations for use on the human skin may be employed in the present invention.
• Suitable excipients include, but are not limited to ingredients that can influence organoleptic properties, penetration of the skin, and the bioavailability of the Mastocarpus stellatus extract.
• liquids such as water, oils or surfactants, including those of petroleum, animal, plant or synthetic origin, such as and not restricted to, peanut oil, soybean oil, mineral oil, sesame oil, castor oil, polysorbates, sorbitan esters, ether sulfates, sulfates, betaines, glycosides, maltosides, fatty alcohols, nonoxynols, poloxamers, polyoxyethylenes, polyethylene glycols, dextrose, glycerol, digitonin, and the like.
• the cosmetic composition of the invention further comprises an anti-ageing agent comprising a mixture of mannose-6-phosphate and mannose, as described in WO 2020/201185.
• an anti-ageing agent comprising a mixture of mannose-6-phosphate and mannose, as described in WO 2020/201185.
• the two extracts 1 and 2 were combined, stirred and heated to reach 60 °C. After 30 minutes of heating, the mixture was immediately filtered at 2.5 pm and 0.3 pm successively to obtain a Mastocarpus stellatus extract according to the invention.
• the extract thus obtained had a pH of about 5.45, a dry mass content of about 1 .63%, a Gardner color of about 2.1 , and a floridoside content of about 0.86 g/l. is on Human Fibroblasts
• Sheared tissue was added to a zirconia oxide bead mix and 700 pl of iST LYSE buffer (Deoxycholate, TCEP and Chloroacetamide) were added. Samples were lysed by two rounds of bead beating cycle. Homogenates were transferred into Diagenode protein extraction tube and co-extracted nucleic acid and organelles were sheared by micro cavitation (Bioruptor Pico, Diagenode). Proteins were solubilized, reduced and alkylated by boiling in iST LYSE buffer (Deoxycholate, TCEP and Chloroacetamide). Protein concentration was determined by the BCA method (Walker JM. The bicinchoninic acid (BCA) assay for protein quantitation.
• BCA bicinchoninic acid
• AFM measurement consists in the acquisition of Force-volume on the dermis as illustrated in Figure 1 .
• To each pixel of the image corresponds a Force-indentation curve, from which the elastic modulus (Ea) is extracted.
• Ea elastic modulus
• Mature adipocytes were obtained from subcutaneous adipose tissue coming from a woman aged 30 who had a Body Mass Index (BMI) of 28.7 kg/m 2 and gave her tissue under informed consent.
• Mature adipocytes were isolated from subcutaneous adipose tissue after digestion by collagenase. The isolated adipocytes were washed with a wash buffer and encapsulated in a peptidic hydrogel to form 3D adipocytes capsules of 25 pl in size. The formation of adipocytes capsules followed an internal standardized protocol to have about the same number of adipocytes between the capsules. Cells were then incubated for 24 h at 37 °C for stabilization.
• BMI Body Mass Index
• the measurement of the mechanical properties of the skin enables to assess the functional state of the elastic tissue structures (elastic fibers, curvature of the connective bundles, wrinkles of the stratum corneum) and the viscous-behaving tissue structures (interstitial fluids, internal adherences).
• the measuring principle is based on the suction method: Negative pressure is created in the device and the skin is drawn into the cylindrical aperture (2 mm in diameter) of the probe. Inside the probe, the penetration depth is determined by an optical measuring system. Each suction phase is followed by a relaxing phase.
• the deformation of the skin by the negative pressure first determines the elastic resistance and then the viscous component, which taken together are representative of the skin firmness.
• the immediate recovery of the skin determines sheer cutaneous elasticity, whereas the delayed return of the skin to its initial position measures the viscoelastic component.
• the collagen level on the oval of the face was measured by SiAscope® after 56 days of a twice-daily application of a cream containing the Mastocarpus Stellatus extract versus a placebo cream.
• the placebo a slight increase was showed relative to DO after 56 days. Comparing the product containing the Mastocarpus Stellatus extract with the placebo, it was found that the Mastocarpus Stellatus extract is able to improve collagen 3.4 times more after 28 days and 2.8 times more after 56 days than the placebo.
• CTAB cetrimonium bromide
• the mixture was incubated for 20 min at room temperature, and the optical density (OD) at 600 nm was measured using a spectrophotometer.
• the IC 5 o was calculated, i.e. the sample concentration at which the AGEs formation was inhibited by 50%. The results are shown in the following table:

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Biotechnology (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Dermatology (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Epidemiology (AREA)
• Botany (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Birds (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Medical Informatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Alternative & Traditional Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Cosmetics (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (6)

Applications Claiming Priority (4)

Publications (1)

Family

ID=86426005

Family Applications (1)

Country Status (7)

Citations (6)

• 2023
  • 2023-05-04 CN CN202380038458.3A patent/CN119173249A/zh active Pending
  • 2023-05-04 KR KR1020247040320A patent/KR20250004097A/ko active Pending
  • 2023-05-04 EP EP23725148.3A patent/EP4518834A1/en active Pending
  • 2023-05-04 JP JP2024565068A patent/JP2025515132A/ja active Pending
  • 2023-05-04 US US18/854,121 patent/US20250248922A1/en active Pending
  • 2023-05-04 WO PCT/EP2023/061743 patent/WO2023213918A1/en not_active Ceased
• 2024
  • 2024-12-04 ZA ZA2024/09302A patent/ZA202409302B/en unknown

Patent Citations (6)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events